CNP-101 Prevents Gluten Challenge Induced Immune Activation in Adults with Celiac Disease

(1) Beth Israel Deaconess Medical Center,Boston,United States

(2) Mayo Clinic,Rochester,United States

(3) Takeda Pharmaceuticals International Co.,Cambridge,United States

(4) COUR Pharmaceuticals Development Co., Inc.,Northbrook,United States



This item was part of the Late breaking abstracts: From eosinophilic oesophagitis to novel obesity therapies (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019